Log in

NYSE:SLSGalena Biopharma Stock Price, Forecast & News

$3.43
-0.15 (-4.19 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.08
Now: $3.43
$3.50
50-Day Range
$1.65
MA: $2.45
$3.66
52-Week Range
$1.46
Now: $3.43
$38.50
Volume202,191 shs
Average Volume464,179 shs
Market Capitalization$23.04 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Develop biopharmaceuticals
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
CUSIPN/A
WebN/A
Phone(917) 438-4353

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$23.04 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive SLS News and Ratings via Email

Sign-up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.

Galena Biopharma (NYSE:SLS) Frequently Asked Questions

How has Galena Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Galena Biopharma's stock was trading at $2.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SLS shares have increased by 60.3% and is now trading at $3.43. View which stocks have been most impacted by Coronavirus.

When is Galena Biopharma's next earnings date?

Galena Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Galena Biopharma.

Has Galena Biopharma been receiving favorable news coverage?

Media stories about SLS stock have trended very negative this week, InfoTrie reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Galena Biopharma earned a daily sentiment score of -3.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutGalena Biopharma.

Who are some of Galena Biopharma's key competitors?

What other stocks do shareholders of Galena Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galena Biopharma investors own include Vaxart (VXRT), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Nabriva Therapeutics (NBRV), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Amarin (AMRN), Protalix Biotherapeutics (PLX), Aduro BioTech (ADRO) and Altimmune (ALT).

Who are Galena Biopharma's key executives?

Galena Biopharma's management team includes the following people:
  • Angelos M. Stergiou, President, Chief Executive Officer & Director
  • Aleksey N. Krylov, Chief Financial Officer, Treasurer & Director
  • Nicholas J. Sarlis, Director, Chief Medical Officer & Senior VP
  • Barbara A. Wood, Secretary, Executive VP & General Counsel
  • Gregory M. Torre, Director, Chief Regulatory Officer & Senior VP

What is Galena Biopharma's stock symbol?

Galena Biopharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "SLS."

How do I buy shares of Galena Biopharma?

Shares of SLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Galena Biopharma's stock price today?

One share of SLS stock can currently be purchased for approximately $3.43.

How big of a company is Galena Biopharma?

Galena Biopharma has a market capitalization of $23.04 million.

How can I contact Galena Biopharma?

The company can be reached via phone at (917) 438-4353.

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.